Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single- and Multiple-Ascending Dose Study of LY3502970 in Japanese Participants with Type 2 Diabetes Mellitus
jRCT2031210420Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of orforglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-emergent adverse events and serious adverse events related to study drug. Started Nov 2021; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031210420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210420.